|
ヤマグチ シゲキ
YAMAGUCHI SHIGEKI
山口 茂樹 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Robot-assisted surgery with Senhance robotic system for colon cancer: our original single-incision plus 2-port procedure and a review of the literature. |
| 掲載誌名 | 正式名：Techniques in coloproctology 略 称：Tech Coloproctol ISSNコード：1128045X/11236337 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 25(4),pp.467-471 |
| 著者・共著者 | Hirano Yasumitsu, Kondo Hiroka, Yamaguchi Shigeki |
| 担当区分 | 最終著者 |
| 発行年月 | 2021/04 |
| 概要 | BACKGROUND:The Senhance robotic system provides such advantages as an eye-tracking camera control system, haptic feedback, operator comfort, and reusable endoscopic instruments. The aim of this small study was to assess the feasibility and safety of performing a reduced-port robot-assisted colectomy for colon cancer with the use of a novel robotic system.METHODS:This was a single-center retrospective study of eight patients with colon cancer who underwent single-incision plus 2-port robot-assisted colectomy with the Senhance robotic system (SILS+2-S) between December 2019 and March 2020 at our hospital. Data on perioperative outcomes, which included operative time, operative blood loss, length of hospitalization, postoperative complications, and histopathological results, were collected prospectively.RESULTS:The mean patient age was 70.9 years and the mean body mass index was 24.4 kg/m2. One patient was converted to laparoscopy due to a damaged scope holder. The mean operative and console times were 229.1 and 139.1 min, respectively. The mean intraoperative blood loss was 49.4 ml. The mean length of the umbilical incision was 3.0 cm. The mean number of harvested lymph nodes was 18.3. The surgical margins were negative in all eight patients. There was neither morbidity nor mortality associated with the procedure, and no Clavien-Dindo classification Grade II-IV complications occurred.CONCLUSIONS:SILS+2-S is a safe and feasible approach for patients with colon cancer. Further studies are needed to validate the advantages of SILS+2-S and to evaluate the long-term oncological outcomes. |
| DOI | 10.1007/s10151-020-02389-1 |
| PMID | 33587212 |